National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Canagliflozin (Invokana®) is indicated for the treatment of type 2 diabetes as monotherapy or add-on combination therapy to other glucose-lowering medicinal products including insulin

Rapid Review

Commenced Completed Outcome
25/11/2013 02/12/2013 Full HTA Recommended

 

Pharmacoeconomic Evaluation

Commenced Completed Outcome
17/04/2014  29/08/2014 Reimbursement not recommended under the submitted pricing structure.

Summary

December 2014

The HSE has approved reimbursement following confidential price negotiations.